Know Your Nodes: Suspicion and Diagnosis of Lymphoma

Pamela Skrabek MD FRCPC

Department of Medical Oncology & Haematology, CancerCare Manitoba

Dept. Internal Medicine, Section of Hematology/Medical Oncology, University of Manitoba



Presenter Disclosure

- Faculty: PS
- Relationships with commercial interests:
 - Grants/Research Support: None
 - Speakers Bureau/Honoraria: None
 - Consulting Fees: Celgene, Roche, Lundbeck, Seattle Genetics, Gilead
 - Other: None



Mitigating Potential Bias

Not Applicable to this talk



Objectives

At the end of this session participants will:

- 1. Have familiarity with the In Sixty Lymphoma Pathway
- 2.Be able to list risk factors for lymphoma and describe common clinical presentations
- 3.Understand the role of different imaging modalities, diagnostic procedures and blood work in the diagnosis of lymphoma




Introduction

- Lymphoma is the 5th most common cancer
 - ~ 300 Manitobans diagnosed each year
- Time to diagnosis longer than other cancers
- Primary Care likely to diagnosis one NHL every
 2-3 years and one HL in career

1. Cancer, N. C. C. f. (2014). Suspected Cancer: recognition and management of suspected cancer in children, young people and adults National Institute for Health and Care Excellence



Simple Classification





Referral

Itanks so much for seeing this lady Ne: laye mass left upper arm. The (Darm 38 on @ 25 cm) this has continued to wellegs. (Darm 38 on @ 25 cm) this has continued to wellegs. X-ray, CT, US, MRI have been done Biophy reg has been sent to HSC. Please see reports en closed. Q discussed case & Dr Boch - he fiels this islikely lyphonea. Monoprilanyol PM HO: type I DM enematord authors · Methotrexale 3,5 mg/wh



- Canadian lifetime probability NHL
 - 1:43 men (2.3%), 1:50 women (2%)
- Very few factors greatly increase risk
 - Primary Immune Disorders (incidence lymphoma 12-25%)
 - Autoimmune Disease, Organ Transplant,
 HIV, Drugs that modulate immune system



- Lifetime probability NHL ~ 2%
- IF first degree relative with NHL, HL or CLL ~1.7 fold, 3.1 fold and 8.5 fold risk respectively of same diagnosis
 - Thus lifetime risk NHL ~ 3.4% even lower specific lymphoma subtypes





Work-Up of Lymphadenopathy Suspicious for LYMPHOMA

Timeline and Legend pg.5


CANCER ACTION

RISK FACTORS: HIGH risk: immune deficiency (ie. HIV or organ transplant), autoimmune disease +/- immune suppressing medications, and history of lymphoma

PRACTICE POINTS: **Consider your differential diagnosis** -reactive LN due to infection (ie:TB) or inflammation, metastatic malignancy and autoimmune disease. This document applies to adults 17 years of age or older.

PRACTICE POINTS: All referrals sent within 24 hrs of visit. Provide <u>complete</u> <u>information as requested</u> to avoid delays. Ensure patient and family is well informed and receives appointment information. If patient is in distress, offer referral to local counsellor. See **Supporting Information for Clinicians** (pg 4) for contacts and resources.

Contact the Cancer Question Helpline for Primary Care for assistance.



- > 30% patients with NHL and > 40% HL have more than 3 visits to Primary Care before investigations/ referrals
- No "symptom signature"
- No screening tests



- Most cases NHL and HL present with lymphadenopathy (LN)
 - May be found incidentally (~ 30%)
- B symptoms seen in aggressive lymphomas especially with high disease burden
 - In isolation neither PPV or Negative Predictive Value (NPV) that high



- LN most common presentation NHL and HL
 - Most peripheral LN is benign
 -What makes LN "suspicious"
 - Size (> 2 cm), persistence, location, multiplicity
 - Clinical context



- Aside from LN most clinical symptoms or signs as single features of low predictive value
- Further 1 PPV of LN when combined with
 - Weight loss, abdominal complaints, dyspnea
 - Leucocytosis, cytopenias, increased liver enzymes, increased inflammatory markers



Approach to Lymphadenopathy

- History, Examine all LN group
 - Size, consistency, fixation, rapidity of growth
 - Local cause
 - oropharynx, liver, spleen
- CBC, Chest X-ray, HIV test
- Suspicion of malignancy order CT scan (imaging test of choice in adults)



Case

- 19 year old female previously well with right neck lymph node (2 x 3 cm)
- Exam otherwise normal
- No symptoms







High Suspicion "red flags"

- Lymphadenopathy + HIGH Risk Patient
- LN + Abnormal Bloodwork (severe anemia, thrombocytopenia, pancytopenia)
- Widespread LN +/- splenomegaly or bulky LN (mass >6cm)
- Mediastinal mass
- LN with rapid growth
- LN & B symptoms (drenching sweats, unexplained fever, weight loss)
- Patient symptomatic from abnormal LN (ie: short of breath, abdominal pain)





Work-Up of Lymphadenopathy Suspicious for LYMPHOMA


Timeline and Legend pg.5

RISK FACTORS: HIGH risk: immune deficiency (ie. HIV or organ transplant), autoimmune disease +/- immune suppressing medications, and history of lymphoma

PRACTICE POINTS: **Consider your differential diagnosis** -reactive LN due to infection (ie:TB) or inflammation, metastatic malignancy and autoimmune disease. This document applies to adults 17 years of age or older.

PRACTICE POINTS: All referrals sent within 24 hrs of visit. Provide <u>complete</u> <u>information as requested</u> to avoid delays. Ensure patient and family is well informed and receives appointment information. If patient is in distress, offer referral to local counsellor. See **Supporting Information for Clinicians** (pg 4) for contacts and resources.

Contact the Cancer Question Helpline for Primary Care for assistance.





Work-Up of Lymphadenopathy Suspicious for LYMPHOMA


Timeline and Legend pg.5

RISK FACTORS: HIGH risk: immune deficiency (ie. HIV or organ transplant), autoimmune disease +/- immune suppressing medications, and history of lymphoma

PRACTICE POINTS: **Consider your differential diagnosis** -reactive LN due to infection (ie:TB) or inflammation, metastatic malignancy and autoimmune disease. This document applies to adults 17 years of age or older.

PRACTICE POINTS: All referrals sent within 24 hrs of visit. Provide <u>complete</u> <u>information as requested</u> to avoid delays. Ensure patient and family is well informed and receives appointment information. If patient is in distress, offer referral to local counsellor. See **Supporting Information for Clinicians** (pg 4) for contacts and resources.

Contact the **Cancer Question Helpline for Primary Care** for assistance.



Diagnosis of Lymphoma

- FNA exclusion metastatic carcinoma, cannot be used for definitive diagnosis
- Open (preferred) or core biopsy required for lymphoma
 - BIOPSY SHOULD BE SENT "LYMPHOMA PROTOCOL" if lymphoma in differential diagnosis




Diagnostic Pathway LYMPHOMA

Timeline and Legend pg.6

PRACTICE POINTS: Consultation with the Lymphoma Disease Site Group can happen earlier in the pathway if clinicians need additional support or guidance.

*Results Consistent with Lymphoma: If flow cytometry from biopsy or FNA is consistent with lymphoma, consult should be sent to CCMB Central Referral for triage by Lymphoma DSG even if final pathology report is not yet complete.

PRACTICE POINTS: Ensure patient is well informed and receives appointment information. Offer patients connections with psychosocial clinicians and cancer navigation services (see **Supporting Information for Clinicians**, pg 5). Ensure the referring primary care provider is informed of results, direct referrals, and result discussions with patients.





Timeline Model in Manitoba for the Lymphoma* Patient Journey from Suspicion of Cancer to Treatment in Sixty Days



*Lymphoma: Goal of suspicion to treatment in under 60 days for patients presenting with concerning features and/or biopsy with aggressive non-Hodgkin lymphoma such as Diffuse Large B-Cell (DLBCL,) Grade 3B Follicular (FL,) Mantle Cell (MCL) or Hodgkin Lymphoma

ţ	Days —							
 High suspicion 	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 50 57 58 5							9 60
	CT Scans		Refer Triage	Hematology Consult		Chemotherapy (Post-PET),		
	Surgery Consult if palp LN	Biopsy	CCMB Illage	Heriatology Con	Radiation Therapy			
		FNA Refer Triage	Pathology Reported & PET Ordered		PET Reported			
1	Visits, Tests and Procedures							



Take Home Messages

- No one presentation of lymphoma
- Patients with abnormal lymphadenopathy need investigation
 - Consider your differential diagnosis
 - If red flags proceed without delay
 - Please use the clinical pathway developed



Questions?



pskrabek@cancercare.mb.ca

